HIM
ADAP

Hillhouse Investment Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Hillhouse Investment Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,190,476
Closed -$5.34M – 50
2017
Q2 		$5.34M Hold
1,190,476
– – 0.08% 46
2017
Q1 		$6.56M Buy
+1,190,476
New +$5.21M 0.13% 40

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Hillhouse Investment Management's ADAP Position: Q3 2017 in Review

Hillhouse Investment Management sold out of Adaptimmune Therapeutics (ADAP) in Q3 2017, closing a stake of 1,190,476 shares — an estimated $5.34M sold.

Hillhouse Investment Management first reported a position in ADAP in Q1 2017 and held it in 2 quarters. The position peaked at $6.56M in Q1 2017. 67 funds tracked by Wall St. Rank hold ADAP as of Q3 2017.

  • Hillhouse Investment Management reported no remaining Adaptimmune Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Hillhouse Investment Management sold 1,190,476 Adaptimmune Therapeutics shares in Q3 2017, an estimated $5.34M.
  • Hillhouse Investment Management first reported a position in Adaptimmune Therapeutics in Q1 2017 and held it in 2 quarters.
  • Hillhouse Investment Management's Adaptimmune Therapeutics position peaked at $6.56M in Q1 2017.
  • 67 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2017.

Based on Hillhouse Investment Management's 13F filing for Q3 2017, filed 14 Nov 2017.